Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 6/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | BCL9 | O00512 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14256145 | 0.93 | USP30 (0.47) | BACE1USP30BACE2 | |
| SCHEMBL4875231 | 0.80 | HSP90AA1 (0.40) | PPARGPPARAHSP90AA1HSP90AB1EPHX2 | |
| SCHEMBL14256143 | 0.72 | JAK2 (0.46) | USP30HSP90AA1HSP90AB1 | |
| SCHEMBL8195190 | 0.68 | USP30 (0.54) | BACE1USP30BACE2 | |
| SCHEMBL6042280 | 0.68 | RAB9A (0.42) | — | |
| SCHEMBL6042842 | 0.67 | REN (0.45) | — | |
| SCHEMBL4066884 | 0.67 | KIF11 (0.42) | HSP90AA1HSP90AB1BCL9CTNNB1 | |
| SCHEMBL19032404 | 0.66 | MEN1 (0.49) | SCN1ASCN2ASCN3A | |
| SCHEMBL19023244 | 0.66 | MEN1 (0.49) | SCN1ASCN2ASCN3A | |
| SCHEMBL19023241 | 0.66 | MEN1 (0.49) | SCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338965-B2 | 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines | PHARMACIA & UPJOHN COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-20040034031-A1 | 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines | ELAN PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034031-A1 | 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines | BACE1, APP, BACE2 | SCN1A 1227/4885SCN2A 820/4885SCN3A 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.